X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 12.2 44.6 27.4% View Chart
P/BV x 3.2 3.8 84.5% View Chart
Dividend Yield % 0.4 0.3 111.2%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
CIPLA
Mar-17
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs993622 159.7%   
Low Rs729458 159.1%   
Sales per share (Unadj.) Rs325.5181.9 179.0%  
Earnings per share (Unadj.) Rs39.312.9 305.3%  
Cash flow per share (Unadj.) Rs48.729.3 166.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.4 62.7%  
Book value per share (Unadj.) Rs159.2155.7 102.3%  
Shares outstanding (eoy) m282.17804.51 35.1%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.63.0 89.1%   
Avg P/E ratio x21.942.0 52.2%  
P/CF ratio (eoy) x17.718.4 96.0%  
Price / Book Value ratio x5.43.5 155.9%  
Dividend payout %5.115.5 32.8%   
Avg Mkt Cap Rs m242,991434,516 55.9%   
No. of employees `00013.023.0 56.3%   
Total wages/salary Rs m16,40826,338 62.3%   
Avg. sales/employee Rs Th7,083.96,349.1 111.6%   
Avg. wages/employee Rs Th1,265.41,143.0 110.7%   
Avg. net profit/employee Rs Th855.1449.3 190.3%   
INCOME DATA
Net Sales Rs m91,857146,302 62.8%  
Other income Rs m3742,287 16.3%   
Total revenues Rs m92,230148,589 62.1%   
Gross profit Rs m20,36724,758 82.3%  
Depreciation Rs m2,64413,229 20.0%   
Interest Rs m2,3731,594 148.9%   
Profit before tax Rs m15,72412,222 128.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,798 212.9%   
Profit after tax Rs m11,08810,354 107.1%  
Gross profit margin %22.216.9 131.0%  
Effective tax rate %24.314.7 165.5%   
Net profit margin %12.17.1 170.6%  
BALANCE SHEET DATA
Current assets Rs m68,74687,370 78.7%   
Current liabilities Rs m27,02733,081 81.7%   
Net working cap to sales %45.437.1 122.4%  
Current ratio x2.52.6 96.3%  
Inventory Days Days8587 97.8%  
Debtors Days Days9662 153.3%  
Net fixed assets Rs m24,132111,567 21.6%   
Share capital Rs m2821,609 17.5%   
"Free" reserves Rs m44,643123,645 36.1%   
Net worth Rs m44,925125,254 35.9%   
Long term debt Rs m45,36336,454 124.4%   
Total assets Rs m117,639209,532 56.1%  
Interest coverage x7.68.7 88.0%   
Debt to equity ratio x1.00.3 347.0%  
Sales to assets ratio x0.80.7 111.8%   
Return on assets %11.45.7 200.7%  
Return on equity %24.78.3 298.6%  
Return on capital %19.18.5 225.3%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m56,15251,066 110.0%   
Fx outflow Rs m8,08417,678 45.7%   
Net fx Rs m48,06833,388 144.0%   
CASH FLOW
From Operations Rs m6,57423,824 27.6%  
From Investments Rs m-7,124-13,127 54.3%  
From Financial Activity Rs m5,432-13,239 -41.0%  
Net Cashflow Rs m1,992-2,478 -80.4%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 26, 2018 09:09 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS